Items tagged with Drug-resistant TB
Revolution in MDR-TB treatment: Shorter all-oral regimens (post)
In a recent review published in the Open Forum Infectious Diseases journal, researchers reported on the evolution of multidrug-resistant tuberculosis (MDR-TB) therapy.
How push from survivors and an HIV support group led to a cheaper TB drug (post)
Advocacy by patients led authorities to reject a patent application for bedaquiline, a drug that shortens treatment and has a higher success rate.
International consensus highlights the importance of molecular testing for antibiotic resistance in TB management (post)
A multidisciplinary group of tuberculosis experts from the TBnet and RESIST-TB networks have reached a consensus on key issues related to the molecular prediction of Mycobacterium tuberculosis antibiotic sensitivity or resistance and its clinical implications. The consensus document provides guidance for the design of therapeutic regimens and the optimization of treatments, and is intended to help clinicians manage tuberculosis patients. The paper, published in The Lancet Infectious Diseases and led by Dr José Domínguez from the Germans Trias i Pujol Research Institute (IGTP), is an update of a similar statement made in 2016. The publication presents a review of the current tools to rapidly identify resistance to drugs used in the treatment of tuberculosis.
RESIST-TB April 2023 newsletter (post)
RESIST-TB released its April 2023 newsletter with the latest updates and research publications on drug-resistant TB.
WHO BPaLM Accelerator Platform: to support the Call to Action for implementation of the shorter and more effective treatment for all people suffering from drug-resistant TB (post)
The World Health Organization (WHO)’s latest guidelines on drug-resistant TB treatment recommend rapid roll-out of the novel BPaLM regimen that has the potential to dramatically increase cure rates due to its high efficacy, allow broader access due to its lower cost and improve patient quality of life as this regimen is all-oral and significantly shorter than conventional treatment regimens. WHO and its partners have recently issued a Call to Action to call on governments and other stakeholders to accelerate the implementation of the novel, 6-month all-oral regimen for the treatment of drug-resistant TB.
Public call for experts with experience in the co-administration of treatment for drug-resistant TB and hepatitis C (post)
A recent systematic review, commissioned by the World Health Organization (WHO), demonstrated that the prevalence of chronic hepatitis C virus (HCV) infection is high among patients with TB. Published evidence on the safety and effectiveness of co-administering treatment for rifampicin-resistant TB and HCV co-infection is extremely scarce and insufficient as a basis to develop global policy recommendations on this intervention.
An estimated 35% of MDR-TB is extensively drug-resistant- or pre-XDR-TB (post)
Among those with MDR-TB included in the meta-analysis, 27% showed resistance to fluoroquinolones and 11% showed resistance to second-line injectable drugs.
RESIST-TB May 2023 newsletter (post)
RESIST-TB released its May 2023 newsletter with the latest updates and research publications on drug-resistant TB.
Real-world management and outcomes of U.S. patients treated with BPaL for rifampin-resistant TB (post)
In a recent study published in the journal Clinical Infectious Diseases, researchers reported on the treatment of rifampin-resistant tuberculosis in the United States (U.S.) using the Food and Drug Administration (FDA) approved bedaquiline, pretomanid, and linezolid (BPaL) therapy.
RESIST-TB June 2023 newsletter (post)
RESIST-TB released its June 2023 newsletter with the latest updates and research publications on drug-resistant TB.
Page 80 of 117 · Total posts: 0
←First 79 80 81 Last→